LAWSUITS NEWS & LEGAL INFORMATION
Pacific Bioscience of California, Inc PACB Securities Stock Fraud
|Company:||Pacific Bioscience of California, Inc|
|Class Period:||Oct-27-10 to Sep-20-11|
|Lead Plaintiff Deadline:||Feb-26-12|
|Court:||Northern District of California|
The PacBio shareholder class action lawsuit, filed in the United States District Court for the Northern District of California, alleges that during the Class Period, the Company materially misled the investing public by failing to disclose material adverse facts regarding the Company' overall operational and financial condition that were caused by significant problems with its third generation human genome sequencing technology.
The Complaint further alleges that as a result of these materially false and misleading statements, PacBio' common stock traded at artificially-inflated prices during the Class Period. Shareholders allege that when the truth concerning the Company' business prospects, and specifically its revenue projections, were finally revealed on September 20, 2011, the price of PacBio common stock drastically fell 24%.
If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.
Pacific Bioscience of California, Inc PACB Securities Fraud Legal HelpIf you have suffered from financial losses, you may qualify for damages or remedies that may be awarded in a possible Pacific Bioscience of California, Inc securities class action lawsuit. Please click the link below to submit your complaint for a free evaluation.
Published on Dec-30-11
READ MORE Securities Settlements and Legal News